

Guglielmo Ronco

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8624900/publications.pdf>

Version: 2024-02-01

116
papers

9,351
citations

71102

41
h-index

38395

95
g-index

124
all docs

124
docs citations

124
times ranked

6331
citing authors

#	ARTICLE	IF	CITATIONS
1	Performance of HPV E6/E7 mRNA assay as primary screening test: Results from the NTCC2 trial. <i>International Journal of Cancer</i> , 2022, 151, 1047-1058.	5.1	21
2	Determinants of p16/Ki67 adequacy and positivity in HPV-positive women from a screening population. <i>Cancer Cytopathology</i> , 2021, 129, 383-393.	2.4	6
3	p16/Ki67 and E6/E7 mRNA Accuracy and Prognostic Value in Triage of HPV DNA-Positive Women. <i>Journal of the National Cancer Institute</i> , 2021, 113, 292-300.	6.3	41
4	Estimating the direct effect of human papillomavirus vaccination on the lifetime risk of screen-detected cervical precancer. <i>International Journal of Cancer</i> , 2021, 148, 320-328.	5.1	7
5	Combined use of cytology, p16 immunostaining and genotyping for triage of women positive for high-risk human papillomavirus at primary screening. <i>International Journal of Cancer</i> , 2020, 147, 1864-1873.	5.1	16
6	Performance indicators in breast cancer screening in the European Union: A comparison across countries of screen positivity and detection rates. <i>International Journal of Cancer</i> , 2020, 147, 1855-1863.	5.1	6
7	Key issues that need to be considered while revising the current annex of the European Council Recommendation (2003) on cancer screening. <i>International Journal of Cancer</i> , 2020, 147, 9-13.	5.1	6
8	Low-grade screen-detected ductal carcinoma in situ progresses more slowly than high-grade lesions: evidence from an international multi-centre study. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 761-765.	2.5	9
9	Response to the author: invitation to cancer screening: putting the car before the horse?. <i>European Journal of Cancer Prevention</i> , 2019, 28, 458-459.	1.3	0
10	Performance of colorectal cancer screening in the European Union Member States: data from the second European screening report. <i>Gut</i> , 2019, 68, 1232-1244.	12.1	113
11	Invitation strategies and coverage in the population-based cancer screening programmes in the European Union. <i>European Journal of Cancer Prevention</i> , 2019, 28, 131-140.	1.3	16
12	Impacts of human papillomavirus vaccination for different populations: A modeling study. <i>International Journal of Cancer</i> , 2018, 143, 1086-1092.	5.1	18
13	Human papilloma virus genotyping for the cross-sectional and longitudinal probability of developing cervical intraepithelial neoplasia grade 2 or more. <i>International Journal of Cancer</i> , 2018, 143, 333-342.	5.1	16
14	Eurogin roadmap 2017: Triage strategies for the management of HPV-positive women in cervical screening programs. <i>International Journal of Cancer</i> , 2018, 143, 735-745.	5.1	124
15	Role of HPV DNA testing in modern gynaecological practice. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2018, 47, 107-118.	2.8	19
16	Status of implementation and organization of cancer screening in The European Union Member States—Summary results from the second European screening report. <i>International Journal of Cancer</i> , 2018, 142, 44-56.	5.1	169
17	Author's reply to: Implementation and organization of cancer screening in France. <i>International Journal of Cancer</i> , 2018, 143, 3035-3035.	5.1	0
18	Cervical Cancer Screening: The Transformational Role of Routine Human Papillomavirus Testing. <i>Annals of Internal Medicine</i> , 2018, 168, 75.	3.9	5

#	ARTICLE	IF	CITATIONS
19	MicroRNAs as markers of progression in cervical cancer: a systematic review. <i>BMC Cancer</i> , 2018, 18, 696.	2.6	135
20	Author's reply to: Cancer screening policy in Hungary. <i>International Journal of Cancer</i> , 2018, 143, 1005-1005.	5.1	0
21	Assessment of viral methylation levels for high risk HPV types by newly designed consensus primers PCR and pyrosequencing. <i>PLoS ONE</i> , 2018, 13, e0194619.	2.5	7
22	Small non-coding RNA profiling in human biofluids and surrogate tissues from healthy individuals: description of the diverse and most represented species. <i>Oncotarget</i> , 2018, 9, 3097-3111.	1.8	56
23	Determinants of Viral Oncogene E6-E7 mRNA Overexpression in a Population-Based Large Sample of Women Infected by High-Risk Human Papillomavirus Types. <i>Journal of Clinical Microbiology</i> , 2017, 55, 1056-1065.	3.9	10
24	Causal system modelling of cervical cancer screening. <i>Lancet Public Health</i> , The, 2017, 2, e61-e62.	10.0	1
25	Interobserver reproducibility of cytologic p16 ^{INK4a} /Ki67 dual immunostaining in human papillomavirus-positive women. <i>Cancer Cytopathology</i> , 2017, 125, 212-220.	2.4	25
26	Different Challenges in Eliminating HPV16 Compared to Other Types: A Modeling Study. <i>Journal of Infectious Diseases</i> , 2017, 216, 336-344.	4.0	20
27	Inequalities in cervical cancer screening utilisation and results: A comparison between Italian natives and immigrants from disadvantaged countries. <i>Health Policy</i> , 2017, 121, 1072-1078.	3.0	9
28	Cervical cancer screening in women vaccinated against human papillomavirus infection: Recommendations from a consensus conference. <i>Preventive Medicine</i> , 2017, 98, 21-30.	3.4	49
29	Impact of variations in triage cytology interpretation on human papillomavirus-based cervical screening and implications for screening algorithms. <i>European Journal of Cancer</i> , 2016, 68, 148-155.	2.8	37
30	Why follow-back studies should be interpreted cautiously: The case of an HPV-negative cervical lesion. <i>Cancer Cytopathology</i> , 2016, 124, 66-67.	2.4	10
31	HPV-FASTER: broadening the scope for prevention of HPV-related cancer. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 119-132.	27.6	154
32	Interpretation of p16 ^{INK4a} /Ki67 dual immunostaining for the triage of human papillomavirus-positive women by experts and nonexperts in cervical cytology. <i>Cancer Cytopathology</i> , 2015, 123, 212-218.	2.4	35
33	Informed Cytology for Triage of HPV-Positive Women: Substudy Nested in the NTCC Randomized Controlled Trial. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	6.3	61
34	European guidelines for quality assurance in cervical cancer screening. Summary of the supplements on HPV screening and vaccination. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2015, 1, 22-31.	4.5	181
35	The clinical impact of using p16 INK4a immunochemistry in cervical histopathology and cytology: An update of recent developments. <i>International Journal of Cancer</i> , 2015, 136, 2741-2751.	5.1	84
36	Changes in cervical cancer incidence following the introduction of organized screening in Italy. <i>Preventive Medicine</i> , 2015, 75, 56-63.	3.4	35

#	ARTICLE	IF	CITATIONS
37	The Age Distribution of Type-Specific High-Risk Human Papillomavirus Incidence in Two Population-Based Screening Trials. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 111-118.	2.5	11
38	Extension of organized cervical cancer screening programmes in Italy and their process indicators, 2011-2012 activity. <i>Epidemiologia E Prevenzione</i> , 2015, 39, 61-76.	1.1	10
39	A first survey of HPV-based screening in routine cervical cancer screening in Italy. <i>Epidemiologia E Prevenzione</i> , 2015, 39, 77-83.	1.1	21
40	The Possible Effects on Socio-Economic Inequalities of Introducing HPV Testing as Primary Test in Cervical Cancer Screening Programs. <i>Frontiers in Oncology</i> , 2014, 4, 20.	2.8	37
41	Efficacy of HPV-Based Screening for Prevention of Invasive Cervical Cancer. <i>Obstetrical and Gynecological Survey</i> , 2014, 69, 472-473.	0.4	1
42	Upscaling human papillomavirus vaccination in high-income countries: impact assessment based on transmission model. <i>Infectious Agents and Cancer</i> , 2014, 9, 4.	2.6	14
43	Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. <i>Lancet, The</i> , 2014, 383, 524-532.	13.7	1,282
44	Age and geographic variability of human papillomavirus high-risk genotype distribution in a large unvaccinated population and of vaccination impact on HPV prevalence. <i>Journal of Clinical Virology</i> , 2014, 60, 257-263.	3.1	25
45	HPV-based screening for prevention of invasive cervical cancer – Authors' reply. <i>Lancet, The</i> , 2014, 383, 1295.	13.7	10
46	Difference in overall and age-specific prevalence of high-risk human papillomavirus infection in Italy: evidence from NTCC trial. <i>BMC Infectious Diseases</i> , 2013, 13, 238.	2.9	19
47	Benefits of catch-up in vaccination against human papillomavirus in medium- and low-income countries. <i>International Journal of Cancer</i> , 2013, 133, 1876-1881.	5.1	14
48	Screening patterns within organized programs and survival of Italian women with invasive cervical cancer. <i>Preventive Medicine</i> , 2013, 57, 220-226.	3.4	37
49	Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial. <i>Lancet Oncology, The</i> , 2013, 14, 168-176.	10.7	139
50	A cross-sectional study to estimate high-risk human papillomavirus prevalence and type distribution in Italian women aged 18–26 years. <i>BMC Infectious Diseases</i> , 2013, 13, 74.	2.9	20
51	Clinical Impact of the Analytical Specificity of the Hybrid Capture 2 Test: Data from the New Technologies for Cervical Cancer (NTCC) Study. <i>Journal of Clinical Microbiology</i> , 2013, 51, 2901-2907.	3.9	26
52	The Present and Future of Cervical Cancer Screening Programmes in Europe. <i>Current Pharmaceutical Design</i> , 2013, 19, 1490-1497.	1.9	12
53	Type-Specific Human Papillomavirus Biological Features: Validated Model-Based Estimates. <i>PLoS ONE</i> , 2013, 8, e81171.	2.5	21
54	The present and future of cervical cancer screening programmes in Europe. <i>Current Pharmaceutical Design</i> , 2013, 19, 1490-7.	1.9	12

#	ARTICLE	IF	CITATIONS
55	HPV Testing Is an Efficient Management Choice for Women With Inadequate Liquid-Based Cytology in Cervical Cancer Screening. <i>American Journal of Clinical Pathology</i> , 2012, 138, 65-71.	0.7	11
56	Evidence Regarding Human Papillomavirus Testing in Secondary Prevention of Cervical Cancer. <i>Vaccine</i> , 2012, 30, F88-F99.	3.8	695
57	Concurrent infections with multiple human papillomavirus (HPV) types in the New Technologies for Cervical Cancer (NTCC) screening study. <i>European Journal of Cancer</i> , 2012, 48, 1633-1637.	2.8	50
58	EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease. <i>International Journal of Cancer</i> , 2012, 131, 1969-1982.	5.1	204
59	HPV prevalence and accuracy of HPV testing to detect high-grade cervical intraepithelial neoplasia. <i>International Journal of Cancer</i> , 2012, 130, 1387-1394.	5.1	44
60	Consent for Research With Biological Samples: One-Time General Consent Versus a Gift Model. <i>Annals of Internal Medicine</i> , 2012, 156, 596.	3.9	11
61	Modelling patterns of clearance of HPV-16 infection and vaccination efficacy. <i>Vaccine</i> , 2011, 29, 1270-1277.	3.8	24
62	HPV types in early-onset cervical cancer. <i>Lancet Oncology</i> , The, 2011, 12, 117.	10.7	2
63	HPV16 and HPV18 genotyping in cervical cancer screening. <i>Lancet Oncology</i> , The, 2011, 12, 831-832.	10.7	7
64	Eurogin 2010 roadmap on cervical cancer prevention. <i>International Journal of Cancer</i> , 2011, 128, 2765-2774.	5.1	75
65	Extension of organised cervical cancer screening programmes in Italy and their process indicators, 2009 activity. <i>Epidemiologia E Prevenzione</i> , 2011, 35, 39-54.	1.1	2
66	Cervical cancer screening in Italy: quality of colposcopy and treatment. 2009 activity. <i>Epidemiologia E Prevenzione</i> , 2011, 35, 78-86.	1.1	1
67	HPV Screening: Available Data and Recommendations for Clinical Practice. <i>Current Cancer Therapy Reviews</i> , 2010, 6, 104-109.	0.3	4
68	The prevention of cervical cancer in HIV-infected women. <i>Aids</i> , 2010, 24, 2579-2580.	2.2	8
69	Accuracy of liquid-based cytology. <i>Cancer Cytopathology</i> , 2010, 118, 203-208.	2.4	16
70	HPV-16 infection and cervical cancer: Modeling the influence of duration of infection and precancerous lesions. <i>Epidemics</i> , 2010, 2, 21-28.	3.0	27
71	Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. <i>Lancet Oncology</i> , The, 2010, 11, 249-257.	10.7	797
72	HPV test shows low sensitivity of Pap screen in older women – Authors' reply. <i>Lancet Oncology</i> , The, 2010, 11, 510-511.	10.7	2

#	ARTICLE	IF	CITATIONS
73	Infections and cancer: the contribution of European research in recent progresses. <i>Epidemiologia E Prevenzione</i> , 2010, 34, 56-61.	1.1	0
74	Occult HCV Infection: An Unexpected Finding in a Population Unselected for Hepatic Disease. <i>PLoS ONE</i> , 2009, 4, e8128.	2.5	66
75	The Reproducibility of CIN Diagnoses Among Different Pathologists. <i>American Journal of Clinical Pathology</i> , 2009, 132, 125-132.	0.7	82
76	Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. <i>International Journal of Cancer</i> , 2009, 124, 516-520.	5.1	557
77	How to evaluate emerging technologies in cervical cancer screening?. <i>International Journal of Cancer</i> , 2009, 125, 2489-2496.	5.1	91
78	Description of the national situation of cervical cancer screening in the member states of the European Union. <i>European Journal of Cancer</i> , 2009, 45, 2685-2708.	2.8	98
79	Cervical cancer screening policies and coverage in Europe. <i>European Journal of Cancer</i> , 2009, 45, 2649-2658.	2.8	132
80	Cervical cancer screening in Europe – Changes over the last 9 years. <i>European Journal of Cancer</i> , 2009, 45, 2629-2631.	2.8	11
81	Process performance of cervical screening programmes in Europe. <i>European Journal of Cancer</i> , 2009, 45, 2659-2670.	2.8	53
82	What's next? Perspectives and future needs of cervical screening in Europe in the era of molecular testing and vaccination. <i>European Journal of Cancer</i> , 2009, 45, 2714-2721.	2.8	44
83	GP5+/6+ SYBR Green methodology for simultaneous screening and quantification of human papillomavirus. <i>Journal of Clinical Virology</i> , 2009, 45, 90-95.	3.1	20
84	New paradigms in cervical cancer prevention: opportunities and risks. <i>BMC Women's Health</i> , 2008, 8, 23.	2.0	24
85	Overview of Human Papillomavirus-Based and Other Novel Options for Cervical Cancer Screening in Developed and Developing Countries. <i>Vaccine</i> , 2008, 26, K29-K41.	3.8	526
86	Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial. <i>Lancet Oncology</i> , The, 2008, 9, 937-945.	10.7	170
87	Results at Recruitment From a Randomized Controlled Trial Comparing Human Papillomavirus Testing Alone With Conventional Cytology as the Primary Cervical Cancer Screening Test. <i>Journal of the National Cancer Institute</i> , 2008, 100, 492-501.	6.3	259
88	The Risk of False-Positive Histology According to the Reason for Colposcopy Referral in Cervical Cancer Screening. <i>American Journal of Clinical Pathology</i> , 2008, 129, 75-80.	0.7	40
89	Extension of organised cervical cancer screening programmes in Italy and their process indicators. <i>Epidemiologia E Prevenzione</i> , 2008, 32, 37-54.	1.1	5
90	Accuracy of liquid based versus conventional cytology: overall results of new technologies for cervical cancer screening: randomised controlled trial. <i>BMJ: British Medical Journal</i> , 2007, 335, 28.	2.3	224

#	ARTICLE	IF	CITATIONS
91	HPV triage for low grade (L-SIL) cytology is appropriate for women over 35 in mass cervical cancer screening using liquid based cytology. <i>European Journal of Cancer</i> , 2007, 43, 476-480.	2.8	65
92	Detection of human papillomavirus type 16 integration in pre-neoplastic cervical lesions and confirmation by DIPS-PCR and sequencing. <i>Journal of Clinical Virology</i> , 2007, 38, 7-13.	3.1	33
93	HPV testing for primary cervical cancer screening. <i>Lancet, The</i> , 2007, 370, 1740-1742.	13.7	28
94	The impact of new technologies in cervical cancer screening: Results of the recruitment phase of a large randomised controlled trial from a public health perspective. <i>International Journal of Cancer</i> , 2007, 121, 2729-2734.	5.1	10
95	The New Technologies for Cervical Cancer Screening randomised controlled trial. An overview of results during the first phase of recruitment. <i>Gynecologic Oncology</i> , 2007, 107, S230-S232.	1.4	17
96	Human Papillomavirus Testing and Liquid-Based Cytology: Results at Recruitment From the New Technologies for Cervical Cancer Randomized Controlled Trial. <i>Journal of the National Cancer Institute</i> , 2006, 98, 765-774.	6.3	275
97	Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. <i>Lancet Oncology, The</i> , 2006, 7, 547-555.	10.7	202
98	Human papillomavirus typing with GP5+/6+ polymerase chain reaction reverse line blotting and with commercial type-specific PCR kits. <i>Journal of Clinical Virology</i> , 2006, 36, 126-132.	3.1	19
99	Chapter 10: New dimensions in cervical cancer screening. <i>Vaccine</i> , 2006, 24, S90-S97.	3.8	95
100	A report on the current status of European research on the use of human papillomavirus testing for primary cervical cancer screening. <i>International Journal of Cancer</i> , 2006, 118, 791-796.	5.1	60
101	Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. <i>International Journal of Cancer</i> , 2006, 119, 2677-2684.	5.1	332
102	Reproductive Factors, Oral Contraceptive Use, and Human Papillomavirus Infection: Pooled Analysis of the IARC HPV Prevalence Surveys. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 2148-2153.	2.5	118
103	Impact of the introduction of organised screening for cervical cancer in Turin, Italy: cancer incidence by screening history 1992-98. <i>British Journal of Cancer</i> , 2005, 93, 376-378.	6.4	34
104	Prevalence of human papillomavirus infection in women in Turin, Italy. <i>European Journal of Cancer</i> , 2005, 41, 297-305.	2.8	94
105	Reproducibility of HPV DNA Testing by Hybrid Capture 2 in a Screening Setting. <i>American Journal of Clinical Pathology</i> , 2005, 124, 716-721.	0.7	90
106	Reproducibility of HPV DNA Testing by Hybrid Capture 2 in a Screening Setting. <i>American Journal of Clinical Pathology</i> , 2005, 124, 716-721.	0.7	54
107	Assessment of specimen adequacy reproducibility: An Italian experience. <i>Diagnostic Cytopathology</i> , 2003, 28, 224-226.	1.0	4
108	Effect of circulation and discussion of cervical smears on agreement between laboratories. <i>Cytopathology</i> , 2003, 14, 115-120.	0.7	9

#	ARTICLE	IF	CITATIONS
109	Impact of the AutoPap (currently focalpoint) primary screening system location guide use on interpretation time and diagnosis. <i>Cancer</i> , 2002, 99, 83-88.	4.1	12
110	A First Survey of Organized Cervical Cancer Screening Programs in Italy. <i>Tumori</i> , 1998, 84, 624-630.	1.1	11
111	Accuracy of the umbilical arteries Doppler flow velocity waveforms in detecting adverse perinatal outcomes in a high-risk population. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 1996, 75, 113-119.	2.8	38
112	The value of the 1981 who histological classification in inter-observer reproducibility and changing pattern of lung cancer. <i>International Journal of Cancer</i> , 1993, 53, 205-208.	5.1	31
113	The differential diagnosis of primary lung cancer: Inter-observer agreement and contribution of specific diagnostic procedures. <i>Journal of Clinical Epidemiology</i> , 1992, 45, 827-833.	5.0	5
114	The length of pregnancy: An echographic reappraisal. <i>Journal of Clinical Ultrasound</i> , 1991, 19, 11-14.	0.8	8
115	Who Has Pap Tests?: Variables Associated with the Use of Pap Tests in Absence of Screening Programmes. <i>International Journal of Epidemiology</i> , 1991, 20, 349-353.	1.9	40
116	Occupation and lung cancer in two industrialized areas of northern Italy. <i>International Journal of Cancer</i> , 1988, 41, 354-358.	5.1	63